Molecular diagnostics in oncology

Speaker: Nicola Normanno

N. Normanno elaborates advantages of testing targeted agents in selected population and potentials for changing a clinical history in cancer patients, European efforts in quality of molecular testing and minimising genotyping errors, use of different multiplex platforms, and the current status of approval and reimbursement of molecular diagnostics in EU.

Discussion Points

  • What can we conclude from testing target agents in the general population vs. testing patients selected via predictive biomarkers?
  • How do we ensure that the molecular testing of tumour samples is of the utmost quality?
  • What kind of platforms exist for molecular characterisation of tumours? What kind of information do they provide?
  • What are the benefits and drawbacks from next generation sequencing vs. standard sequencing?
  • What is the current status in Europe for the approval and reimbursement of molecular diagnostics?